Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,422.20
(
-1.28%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.95
(
0.73%
)
Bitcoin
80,740.00
(
-0.39%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 96751

Monday, 06/07/2010 5:35:26 PM

Monday, June 07, 2010 5:35:26 PM

Post# of 257566
Re: Teva’s ‘low-volume’ Copaxone

Before I remove #msg-50939364 from one of the yellow sticky slots, I’d like to solicit feedback to my assertion that this product is a marketing and patent-protection gimmick rather than a bona fide medical advance. This matter could be consequential to MNTA’s future, so I expected some MNTA longs to voice an opinion. T.i.a.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today